Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Bristol-Myers Squibb
Related studies linked through entity extraction aliases.
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
- Status
- COMPLETED
- Phase
- N/A
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
- Status
- COMPLETED
- Phase
- N/A
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
- Status
- UNKNOWN
- Phase
- PHASE3
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma
- Status
- COMPLETED
- Phase
- N/A
Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France
- Status
- COMPLETED
- Phase
- N/A
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks
- Status
- COMPLETED
- Phase
- PHASE3
Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada
- Status
- COMPLETED
- Phase
- N/A
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pharmacokinetic Effect of Evotaz/Microgynon Co-administration
- Status
- TERMINATED
- Phase
- PHASE1
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the US
- Status
- COMPLETED
- Phase
- N/A
A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
- Status
- COMPLETED
- Phase
- PHASE2